Amyloidosis Treatment Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Amyloidosis Treatment Market is segmented By Type (Light-chain (AL) amyloidosis, AA amyloidosis, Transthyretin amyloidosis (ATTR), Dialysis-Related Amyloidosis, Others), By Treatment (Chemotherapy, Supportive care, Surgery, Stem Cell Transplant, Targeted Therapy Others), By Drugs (Transthyretin Transport Inhibitor, Immunomodulatory Drugs, Monoclonal Antibodies, Proteasome Inhibitors, Others), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Amyloidosis Treatment Market Overview

The Global Amyloidosis Treatment Market report analyses the size, shares, recent trends, competitive intelligence, and future market outlook. Amyloidosis treatment used to treat amyloidosis diseases is on the rise. Demand from hospital pharmacies and retail pharmacies in the USA is booming. The competitive rivalry intensifies with Merck & Co., Pfizer Inc., AstraZeneca plc. and others active in the market.

An amyloidosis is a group of rare diseases characterized by the buildup of amyloids (aggregates of proteins) that are folded in an incorrect way and get deposited in several organs. The most commonly affected organs include the heart, kidneys, liver, soft tissue, peripheral nervous system, and gastrointestinal tract.

Amyloidosis Treatment Market Scope

For More Insights Request Free Sample

Amyloidosis Treatment Market Dynamics

The global amyloidosis treatment market growth is driven by the emergence of drugs used to treat risk associated with amyloidosis and the high demand for disease-specific novel therapies are the key factors that fuel the market growth.

The increasing cases of amyloidosis are expected to drive the market growth in the forecast period. 

In the U.S., amyloidosis is the most common type, with approximately 3,900 new cases diagnosed every year. The median age of diagnosis for this disease variant is mid-60. Its annual incidence is about 14 cases per million people in western countries, which is approximately one-fifth of that of multiple myeloma, a blood cancer caused by clonal plasma cells in the bone marrow. Furthermore, symptoms such as weight loss, fatigue, edema, and paresthesia often overlap with other common diseases, making its diagnosis difficult.

Amyloidosis is associated with a high mortality rate of approximately 35% within one year of diagnosis, with a median survival between 12 and 18 months. The overall survival in this disease is poorer than multiple myeloma, which shares certain similarities with amyloidosis in relation to both pathogenesis and treatment options. These factors are driving the market growth in the forecast period.

Favorable investments in different countries are projected, expected to drive the market growth

The governments of various countries are investing in their research & development for drugs and other treatment methods for amyloidosis. Some developed economies have advanced medical treatments and technologically advanced diagnostics also. Thus with increased support from government or other authorizing bodies, the market in such regions will flourish. Moreover, the rising awareness about the rare disease and increasing attention towards heredity-related disorders in the general population is anticipated to create the demand for amyloidosis treatment, subsequently offering growth opportunities for the amyloidosis treatment market.

Resulting in the rapid uptake of currently available therapies in the market, thereby creating an imbalanced demand and supply scenario for the amyloidosis treatment market. The increasing investment in the amyloidosis treatment market and increasing reimbursement facilities in developed countries such as U.S. and Germany is anticipated to drive the amyloidosis treatment market.

The high cost involved in treatment is likely to hinder the market growth

However, the high cost involved in treatment and limited awareness may hinder the growth of the overall market. Moreover, limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals are acting as a challenging factor for the growth of this market.

COVID-19 Impact on Amyloidosis Treatment Market Growth

Patients with amyloidosis are vulnerable during the COVID-19 pandemic due to the immune compromise from the plasma cell disorder and therapy-related immune defects. The management of amyloidosis must be individualized on the clinical characteristics, centers’ access to care under the pandemic restrictions, and the epidemiological aspects of the outbreak. Thus the pandemic has driven the growth of the market in the forecast period.

Amyloidosis Treatment Market Segment Analysis

Light-chain (AL) amyloidosis, the segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)  

Light-chain (AL) amyloidosis can affect the kidneys, spleen, heart, and other organs. People with conditions such as multiple myeloma or a bone marrow illness called Wadenström’s macroglobulinemia are more likely to have AL amyloidosis. AL starts in plasma cells within the bone marrow. Plasma cells create antibodies with both heavy chain and light chain proteins. If the plasma cells undergo abnormal changes, they produce excess light chain proteins that can end up in the bloodstream. These damaged protein bits can accumulate in the body’s tissues and damage vital organs such as the heart. Thus its growing prevalence on geratic population is driving its growth in the forecast period.

AA amyloidosis is caused by fragments of amyloid A protein and affects the kidneys in about 80 percent of cases. It can complicate chronic diseases characterized by inflammation, such as rheumatoid arthritis (RA) or inflammatory bowel disease (IBS).

Transthyretin amyloidosis (ATTR) can be inherited from a family member (familial amyloidosis). People of African descent may be more likely to carry the gene that causes this kind of amyloidosis. Transthyretin is a protein that is also known as prealbumin. It is made in the liver. Excessive normal (wild-type ATTR) or mutant transthyretin can cause amyloid deposits.

The hospital pharmacy is expected to dominate the amyloidosis treatment market during the forecast period

The hospital pharmacies held the largest share in the amyloidosis treatment market. This is mainly owing to the increasing number of patients suffering from conditions that are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, the growing number of hospitals along with adequate reimbursement policies is also contributing to the growth of this segment.

Amyloidosis Treatment Market Geographical Share

North America region holds the largest market share global amyloidosis treatment market

North America region is dominating the global amyloidosis treatment market accounted for the largest market share in 2020. The potential launch of pipeline drugs increased adoption of novel therapeutics, and the high cost of treatment in the U.S. is a few factors responsible for its dominant share. An estimated 16,000 people in the U.S. suffer from amyloidosis, with approximately 3,000 to 4,000 new cases being reported annually. Drug development and approval in the country are also growing rapidly. These factors are driving the market growth in the region.

Amyloidosis Treatment Companies and Competitive Landscape

The amyloidosis treatment market is moderately competitive with the presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Merck & Co., Pfizer Inc., AstraZeneca plc. Prothena Corporation plc. , Ionis Pharmaceuticals, Inc., Bellus Health Inc., Alnylam Pharmaceuticals, Inc., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the amyloidosis treatment market globally.    

Amyloidosis Treatment Market Key Companies to Watch

Pfizer Inc.

Overview: Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Product Portfolio: The Company operates in three business segments: healthcare, animal health, and consumer healthcare. Pfizer is the company behind well-known consumer products such as Listerine, Rolaids, Sudafed, and Visine, but the company's greatest revenue producers are its prescription drugs.

Key Development: In May 2019, Pfizer Inc, received approval from the FDA for both Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis), an oral transthyretin stabilizer for the treatment of hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. The FDA approval of Vyndaqel and Vyndamax greatly enhance the company’s business portfolio in the therapeutic area of metabolic disorders.

The global amyloidosis treatment market report would provide an access to an approx. 70 market data table, 68 figures, and 180 pages.